Comparison of the effect of Venlafaxine and Oxybutynin in the Treatment of Hot Flashes

A comparative study of the effect of Venlafaxine and Oxybutynin in controlling Hot Flashes in patients with Breast Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210822052256N1

Enrollment

Registered

2021-10-27

Start date

2021-11-11

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group: Venlafaxine 37.5 mg tablets one tablet per day for 8 weeks Product of Loghman Pharmaceutical Company. Intervention 2: Intervention group: Oxybutynin 10 mg tablets,

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 18 years or older Pre-menopause At least 6 months have passed since the last Menstrual Period. Hot Flashes attacks Willingness to participate in the study

Exclusion criteria

Exclusion criteria: Uncontrolled Hypertension Chronic Heart Failure Chronic Kidney Disease Chronic Lung Failure Chronic Liver Failure Pregnancy Breast feeding Taking Anti Depressant Drugs Taking other Medications to control Hot Flashes over the past Two weeks

Design outcomes

Primary

Measure	Time frame
Severity of Hot Flashes. Timepoint: At the beginning of the study and 8 weeks after taking Venlafaxine or Oxybutynin. Method of measurement: Check List.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Akhavan

Esfahan University of Medical Sciences

aliakhavan@med.mui.ac.ir+98 31 3235 0210

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026